UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

Journal of clinical oncology, 2012-07, Vol.30 (21), p.2691-2697

2012

Volltextzugriff (PDF)

Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma

Journal der Deutschen Dermatologischen Gesellschaft, 2011-04, Vol.9 (4), p.277-286

2011

Volltextzugriff (PDF)

Feasibility of assessing utilities with a single-item standard gamble questionnaire in patients with melanoma

Journal of patient-reported outcomes, 2021-08, Vol.5 (1), p.78-78, Article 78

2021

Volltextzugriff (PDF)

Quality of life under treatment with the immune checkpoint inhibitors ipilimumab and nivolumab in melanoma patients. Real-world data from a prospective observational study at the Skin Cancer Center Kiel

Journal of cancer research and clinical oncology, 2024-10, Vol.150 (10), p.454, Article 454

2024

Volltextzugriff (PDF)

Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study

Frontiers in oncology, 2021-05, Vol.11, p.672172-672172

2021

Volltextzugriff (PDF)

Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy

Cancer treatment reviews, 2016-04, Vol.45, p.7-18

2016

Volltextzugriff (PDF)

Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life

European journal of cancer (1990), 2022-11, Vol.176, p.88-99

2022

Volltextzugriff (PDF)

Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders

Cancer Immunology, Immunotherapy, 2018-05, Vol.67 (5), p.825-834

2018

Volltextzugriff (PDF)

SARS-CoV-2 infections in melanoma patients treated with PD-1 inhibitors: A survey of the German ADOREG melanoma registry

European journal of cancer (1990), 2021-02, Vol.144, p.382-385

2021

Volltextzugriff (PDF)

Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockade

European journal of cancer (1990), 2024-03, Vol.200, p.113536-113536, Article 113536

2024

Volltextzugriff (PDF)

Side effect management during immune checkpoint blockade using CTLA‐4 and PD‐1 antibodies for metastatic melanoma – an update

Journal der Deutschen Dermatologischen Gesellschaft, 2020-06, Vol.18 (6), p.582-609

2020

Volltextzugriff (PDF)

Increased risk of immune checkpoint inhibitor–induced type 1 diabetes mellitus with the new approved 6-week scheme of pembrolizumab in patients with melanoma?

European journal of cancer (1990), 2020-10, Vol.138, p.169-171

2020

Volltextzugriff (PDF)

Influence of adjuvant therapies on organ-specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry ADOReg

International journal of cancer, 2024-07, Vol.155 (10), p.1808-1823

2024

Volltextzugriff (PDF)

Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis

Cancer Immunology, Immunotherapy, 2016-08, Vol.65 (8), p.951-959

2016

Volltextzugriff (PDF)

Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy – A multicentre study of 90 patients from the German Dermatooncology Group

European journal of cancer (1990), 2021-05, Vol.149, p.1-10

2021

Volltextzugriff (PDF)

Effective and Tolerable Treatment of Advanced Basal Cell Carcinoma With Vismodegib Despite Renal Insufficiency

JAMA dermatology (Chicago, Ill.), 2016-12, Vol.152 (12), p.1387

2016

Volltextzugriff (PDF)

Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors’ perspective

Journal of cancer research and clinical oncology, 2024-05, Vol.150 (5), p.252, Article 252

2024

Volltextzugriff (PDF)

Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in Germany: the non-interventional study coveNIS

Melanoma research, 2024-02, Vol.34 (1), p.44-53

2024

Volltextzugriff (PDF)

The side effect registry immuno-oncology (SERIO) – A tool for systematic analysis of immunotherapy-induced side effects

European journal of cancer (1990), 2024-03, Vol.199, p.113505-113505, Article 113505

2024

Volltextzugriff (PDF)

Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition

European journal of cancer (1990), 2021-05, Vol.148, p.61-75

2021

Volltextzugriff (PDF)

Stereotactic radiosurgery combined with immune checkpoint inhibitors or kinase inhibitors for patients with multiple brain metastases of malignant melanoma

Melanoma research, 2019-04, Vol.29 (2), p.187-195

2019

Volltextzugriff (PDF)

Current recommendations for prevention and therapy of extravasation reactions in dermato-oncology

Journal der Deutschen Dermatologischen Gesellschaft, 2009-01, Vol.7 (1), p.21-28

2009

Volltextzugriff (PDF)

Rare cutaneous side effect of vemurafenib : Fever and exanthema 14 days after therapy initiation

Hautarzt, 2021-11, Vol.72 (11), p.1014-1016

2021

Volltextzugriff (PDF)

1 – 25 von 42

Suche als RSS-Feed

Aktive Filter

ThemaAntineoplastic Agents - Therapeutic Use

ThemaPatients

ThemaLife Sciences & Biomedicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(38)

Publikationsform

Artikel
(42)

Sprache

Englisch
(40)
Deutsch
(2)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma

Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse events

Feasibility of assessing utilities with a single-item standard gamble questionnaire in patients with melanoma

Quality of life under treatment with the immune checkpoint inhibitors ipilimumab and nivolumab in melanoma patients. Real-world data from a prospective observational study at the Skin Cancer Center Kiel

Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study

Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy

Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life

Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders

Hematological immune related adverse events after treatment with immune checkpoint inhibitors

SARS-CoV-2 infections in melanoma patients treated with PD-1 inhibitors: A survey of the German ADOREG melanoma registry

Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockade

Side effect management during immune checkpoint blockade using CTLA‐4 and PD‐1 antibodies for metastatic melanoma – an update

Increased risk of immune checkpoint inhibitor–induced type 1 diabetes mellitus with the new approved 6-week scheme of pembrolizumab in patients with melanoma?

Influence of adjuvant therapies on organ-specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry ADOReg

Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis

Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy – A multicentre study of 90 patients from the German Dermatooncology Group

Effective and Tolerable Treatment of Advanced Basal Cell Carcinoma With Vismodegib Despite Renal Insufficiency

Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors’ perspective

Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in Germany: the non-interventional study coveNIS

The side effect registry immuno-oncology (SERIO) – A tool for systematic analysis of immunotherapy-induced side effects

Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition

Stereotactic radiosurgery combined with immune checkpoint inhibitors or kinase inhibitors for patients with multiple brain metastases of malignant melanoma

Current recommendations for prevention and therapy of extravasation reactions in dermato-oncology

Rare cutaneous side effect of vemurafenib : Fever and exanthema 14 days after therapy initiation

Aktive Filter

Suchergebnisse filtern